Martin van Eickels

8.7k total citations · 4 hit papers
72 papers, 6.0k citations indexed

About

Martin van Eickels is a scholar working on Cardiology and Cardiovascular Medicine, Internal Medicine and Molecular Biology. According to data from OpenAlex, Martin van Eickels has authored 72 papers receiving a total of 6.0k indexed citations (citations by other indexed papers that have themselves been cited), including 58 papers in Cardiology and Cardiovascular Medicine, 16 papers in Internal Medicine and 12 papers in Molecular Biology. Recurrent topics in Martin van Eickels's work include Atrial Fibrillation Management and Outcomes (44 papers), Cardiac Arrhythmias and Treatments (32 papers) and Venous Thromboembolism Diagnosis and Management (16 papers). Martin van Eickels is often cited by papers focused on Atrial Fibrillation Management and Outcomes (44 papers), Cardiac Arrhythmias and Treatments (32 papers) and Venous Thromboembolism Diagnosis and Management (16 papers). Martin van Eickels collaborates with scholars based in Germany, United States and United Kingdom. Martin van Eickels's co-authors include Christian Grohé, Stefan H. Hohnloser, Christophe Gaudin, Christian Torp‐Pedersen, Harry J.G.M. Crijns, Richard L. Page, Stuart J. Connolly, Sylvia Haas, Gregory Y.H. Lip and Freek W.A. Verheugt and has published in prestigious journals such as New England Journal of Medicine, Journal of Biological Chemistry and Circulation.

In The Last Decade

Martin van Eickels

72 papers receiving 5.8k citations

Hit Papers

Prevention of Bleeding in Patients with Atrial Fibr... 2009 2026 2014 2020 2016 2009 2013 2015 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI
    2016 942 citations C. Michael Gibson, Roxana Mehran et al. New England Journal of Medicine profile →
  2. Effect of Dronedarone on Cardiovascular Events in Atrial Fibrillation
    2009 707 citations Stefan H. Hohnloser, Harry J.G.M. Crijns et al. New England Journal of Medicine profile →
  3. Risk Profiles and Antithrombotic Treatment of Patients Newly Diagnosed with Atrial Fibrillation at Risk of Stroke: Perspectives from the International, Observational, Prospective GARFIELD Registry
    2013 343 citations Ajay K. Kakkar, Jean‐Pierre Bassand et al. PLoS ONE profile →
  4. XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation
    2015 331 citations A. John Camm, Pierre Amarenco et al. European Heart Journal profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Martin van Eickels Germany 33 4.7k 1.3k 760 612 574 72 6.0k
Nauder Faraday United States 27 1.5k 0.3× 380 0.3× 356 0.5× 394 0.6× 218 0.4× 79 2.8k
Gian Gastone Neri Serneri Italy 34 1.8k 0.4× 377 0.3× 574 0.8× 367 0.6× 102 0.2× 118 3.3k
Hirofumi Soejima Japan 35 2.0k 0.4× 226 0.2× 652 0.9× 631 1.0× 94 0.2× 126 3.9k
Ken Okumura Japan 45 4.5k 1.0× 518 0.4× 1.2k 1.5× 309 0.5× 83 0.1× 268 7.4k
Masaharu Akao Japan 41 3.5k 0.7× 576 0.4× 1.8k 2.3× 99 0.2× 65 0.1× 231 5.7k
Shih-Ann Chen Taiwan 45 5.6k 1.2× 289 0.2× 967 1.3× 155 0.3× 55 0.1× 200 6.4k
Victor A. Umans Netherlands 28 2.8k 0.6× 212 0.2× 793 1.0× 321 0.5× 71 0.1× 146 4.0k
Shusuke Yagi Japan 32 1.3k 0.3× 128 0.1× 1.0k 1.3× 668 1.1× 122 0.2× 175 3.6k
Seibu Mochizuki Japan 27 1.6k 0.3× 99 0.1× 783 1.0× 643 1.1× 177 0.3× 136 3.0k
Toshiaki Ebina Japan 32 1.8k 0.4× 175 0.1× 808 1.1× 330 0.5× 69 0.1× 197 3.4k

Countries citing papers authored by Martin van Eickels

Since Specialization
Citations

This map shows the geographic impact of Martin van Eickels's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Martin van Eickels with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Martin van Eickels more than expected).

Fields of papers citing papers by Martin van Eickels

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Martin van Eickels. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Martin van Eickels. The network helps show where Martin van Eickels may publish in the future.

Co-authorship network of co-authors of Martin van Eickels

This figure shows the co-authorship network connecting the top 25 collaborators of Martin van Eickels. A scholar is included among the top collaborators of Martin van Eickels based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Martin van Eickels. Martin van Eickels is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Verheugt, Freek W.A., Giuseppe Ambrosio, Dan Atar, et al.. (2019). Outcomes in Newly Diagnosed Atrial Fibrillation and History of Acute Coronary Syndromes: Insights from GARFIELD-AF. The American Journal of Medicine. 132(12). 1431–1440.e7. 9 indexed citations
2.
Chi, Gerald, Megan K. Yee, Arzu Kalaycı, et al.. (2018). Total bleeding with rivaroxaban versus warfarin in patients with atrial fibrillation receiving antiplatelet therapy after percutaneous coronary intervention. Journal of Thrombosis and Thrombolysis. 46(3). 346–350. 8 indexed citations
3.
Bassand, Jean‐Pierre, Gabriele Accetta, Wael Al Mahmeed, et al.. (2018). Risk factors for death, stroke, and bleeding in 28,628 patients from the GARFIELD-AF registry: Rationale for comprehensive management of atrial fibrillation. PLoS ONE. 13(1). e0191592–e0191592. 77 indexed citations
4.
Turpie, Alexander G.G., LG Mantovani, Sylvia Haas, et al.. (2017). A Pooled Analysis of the Xalia and Xalia-Lea Non-Interventional Studies of Rivaroxaban Versus Standard Anticoagulation in Venous Thromboembolism. Blood. 130. 2386–2386. 2 indexed citations
5.
Camm, A. John, Gabriele Accetta, Wael Al Mahmeed, et al.. (2017). Impact of gender on event rates at 1 year in patients with newly diagnosed non-valvular atrial fibrillation: contemporary perspective from the GARFIELD-AF registry. BMJ Open. 7(3). e014579–e014579. 31 indexed citations
6.
Turpie, Alexander G.G., LG Mantovani, Sylvia Haas, et al.. (2017). Analysis of patients with deep vein thrombosis switched from standard therapy to rivaroxaban in the non-interventional XALIA study. Thrombosis Research. 155. 23–27. 8 indexed citations
7.
Camm, A. John, Pierre Amarenco, Sylvia Haas, et al.. (2017). REAL-WORLD VERSUS RANDOMIZED TRIAL OUTCOMES IN SIMILAR POPULATIONS OF RIVAROXABAN-TREATED PATIENTS WITH NONVALVULAR ATRIAL FIBRILLATION IN ROCKET AF AND XANTUS. Journal of the American College of Cardiology. 69(11). 438–438. 1 indexed citations
8.
9.
Oh, Seil, Shinya Goto, Gabriele Accetta, et al.. (2016). Vitamin K antagonist control in patients with atrial fibrillation in Asia compared with other regions of the world: Real-world data from the GARFIELD-AF registry. International Journal of Cardiology. 223. 543–547. 63 indexed citations
10.
11.
Camm, A. John, Pierre Amarenco, Sylvia Haas, et al.. (2015). XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation. European Heart Journal. 37(14). 1145–1153. 331 indexed citations breakdown →
12.
Hohnloser, S. H., Harry J.G.M. Crijns, Martin van Eickels, et al.. (2010). Dronedarone in patients with congestive heart failure: insights from ATHENA. European Heart Journal. 31(14). 1717–1721. 45 indexed citations
13.
Hohnloser, Stefan H., Harry J.G.M. Crijns, Martin van Eickels, et al.. (2009). Effect of Dronedarone on Cardiovascular Events in Atrial Fibrillation. New England Journal of Medicine. 360(7). 668–678. 707 indexed citations breakdown →
14.
Zhou, Zongmin, Anastasia Pyriochou, Αναστασία Κοτανίδου, et al.. (2008). Soluble guanylyl cyclase activation by HMR-1766 (ataciguat) in cells exposed to oxidative stress. American Journal of Physiology-Heart and Circulatory Physiology. 295(4). H1763–H1771. 41 indexed citations
15.
Holtwick, Rita, Martin van Eickels, Boris V. Skryabin, et al.. (2003). Pressure-independent cardiac hypertrophy in mice with cardiomyocyte-restricted inactivation of the atrial natriuretic peptide receptor guanylyl cyclase-A. Journal of Clinical Investigation. 111(9). 1399–1407. 290 indexed citations
16.
Eickels, Martin van, Richard D. Patten, Mark Aronovitz, et al.. (2003). 17-Beta-Estradiol increases cardiac remodeling and mortality in mice with myocardial infarction. Journal of the American College of Cardiology. 41(11). 2084–2092. 68 indexed citations
17.
Karas, Richard H., Martin van Eickels, John P. Lydon, et al.. (2001). A complex role for the progesterone receptor in the response to vascular injury. Journal of Clinical Investigation. 108(4). 611–618. 42 indexed citations
18.
Kahlert, Stefan, et al.. (2000). Estrogen Receptor α Rapidly Activates the IGF-1 Receptor Pathway. Journal of Biological Chemistry. 275(24). 18447–18453. 384 indexed citations
19.
Kahlert, Stefan, et al.. (1998). Angiotensin converting enzyme inhibition modulates cardiac fibroblast growth. Journal of Hypertension. 16(3). 377–384. 24 indexed citations
20.
Grohé, Christian, Stefan Kahlert, Martin van Eickels, et al.. (1997). Effects of moexiprilat on oestrogen‐stimulated cardiac fibroblast growth. British Journal of Pharmacology. 121(7). 1350–1354. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Nauder Faraday Breakdown of academic impact, for papers by Gian Gastone Neri Serneri Breakdown of academic impact, for papers by Hirofumi Soejima Breakdown of academic impact, for papers by Ken Okumura Breakdown of academic impact, for papers by Masaharu Akao Breakdown of academic impact, for papers by Shih-Ann Chen Breakdown of academic impact, for papers by Victor A. Umans Breakdown of academic impact, for papers by Shusuke Yagi Breakdown of academic impact, for papers by Seibu Mochizuki Breakdown of academic impact, for papers by Toshiaki Ebina
Rankless by CCL
2026